OPQ- Drug Sampling and Testing Program

The Food and Drug Administration is forecasting a procurement under the OPQ Drug Sampling and Testing Program, targeting vendors with expertise in pharmaceutical sampling and laboratory testing services. The opportunity is classified under NAICS code 424210, indicating a focus on wholesale trade of pharmaceuticals and biological products, suggesting the contract may involve logistics, handling, and distribution of drug samples in conjunction with analytical testing. The agency has not yet released a solicitation number or set-aside details, and the place of performance and office address details remain unspecified, implying the work could be performed at multiple locations under FDA oversight. Point of contact for program inquiries is the CDER Acquisition Liaison via cderacquisitions@fda.hhs.gov, while the contracting officer position is currently vacant and will be filled prior to formal solicitation. This forecast indicates a pending acquisition aimed at ensuring the integrity and safety of drug products through systematic sampling and rigorous laboratory testing procedures. The program likely supports the FDA’s regulatory responsibilities by enabling accurate assessment of drug quality, adulteration, and compliance with federal standards. Interested parties should monitor the official OSDBU portal for the formal solicitation, as details regarding contract structure, performance requirements, timelines, and submission deadlines will be finalized and published in a future announcement. Vendors are advised to prepare documentation demonstrating capability in pharmaceutical handling, chain-of-custody protocols, certified laboratory testing, and compliance with FDA regulatory frameworks.